Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1295784 10.3389/fphar.2023.1295784 Pharmacology Correction Corrigendum: Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy Yi et al. 10.3389/fphar.2023.1295784 Yi Jia-Qin 1 † Huang Sheng 1 † Wu Miao-Juan 1 Ma Jie-Hui 1 Huang Li-Juan 1 Liang Song 2 * Sun Dan 1 * 1 Department of Neurology, Wuhan Children’s Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China 2 Department of Pediatric Rehabilitation, Hubei the Third People’s Hospital, Wuhan, China

Edited and reviewed by: Alfredo Vannacci, University of Florence, Italy

 *Correspondence: Song Liang, song11963@163.com; Dan Sun, bloveriver@163.com

These authors have contributed equally to this work

 29 09 2023 2023 14 1295784 17 09 2023 19 09 2023 Copyright © 2023 Yi, Huang, Wu, Ma, Huang, Liang and Sun. 2023 Yi, Huang, Wu, Ma, Huang, Liang and Sun

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Comparison of the effectiveness and safety of perampanel and oxcarbazepine as monotherapy in children and adolescents with newly diagnosed focal epilepsy by Yi J-Q, Huang S, Wu M-J, Ma J-H, Huang L-J, Liang S and Sun D (2023). Front. Pharmacol. 14:1189058. doi: 10.3389/fphar.2023.1189058 perampanel oxcarbazepine newly diagnosed focal epilepsy monotherapy anti-seizure medications section-at-acceptance Obstetric and Pediatric Pharmacology

In the published article, there was an error in Figure 2 as published. The 3-month seizure freedom rate in OXC group should be 80.7% in the original figure. The 6-month seizure freedom rate in OXC group should be 43/55. The corrected Figure 2 and its caption appear below.

Seizure-response status and seizure-free status on PER/OXC monotherapy. (A) OP3; (B) OP6; and (C) OP12. Seizure free: seizure freedom; Sz reduce ≥75%: seizure reduction ≥75%; Sz reduce ≥50%: seizure reduction ≥50%.

In the published article, there was also an error in the text. The 6-month seizure freedom rate in OXC group should be 43/55.

A correction has been made to 3 Result, 3.2 Primary endpoint, paragraph 1. This sentence previously stated:

“In the PPS, 78.1% (50/64, 95% CI: 66.0%–87.5%) of children in the PER group and 78.2% (43/56) in the OXC group were seizure-free at 6 months.”

The corrected sentence appears below:

“In the PPS, 78.1% (50/64, 95% CI: 66.0%–87.5%) of children in the PER group and 78.2% (43/55) in the OXC group were seizure-free at 6 months.”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.